International AIDS Society
International AIDS Society

Industry Liaison Forum

The International AIDS Society-Industry Liaison Forum (IAS-ILF) is a mechanism to inform and support collaboration and partnership between industry and the IAS. Guided by a strong, multi-stakeholder advisory group, it performs this broad task by regularly providing opportunities for industry to understand the IAS’s interests and priorities, and vice versa, seeking common ground to enhance the impact of our response to HIV and related co-morbidities.

What's New

2013 Annual Report

The IAS-ILF 2013 Annual Report is now available for download.

Industry roundtable on paediatric ARVs

The International AIDS Society–Industry Liaison Forum (IAS-ILF) recently convened industry and non-industry stakeholders to a roundtable on paediatric antiretrovirals (ARVs), entitled “Paediatric antiretrovirals: The barriers to and solutions for improved access to optimal drugs in resource-limited settings” (27 November, Geneva, Switzerland). The meeting, attended by paediatric ARV manufacturers (both originators and generics) and other stakeholders with vested interest in paediatric treatment and care, directly followed the World Health Organization (WHO) manufacturers and stakeholders’ meeting on ARV forecast and demand (25-26 November, Geneva). The main objective was to allow a dialogue with global partners and stakeholders on better coordination and collaboration while also informing the various stakeholders, in particular industry, about the on-going global efforts addressing challenges specific to paediatric ARVs (e.g., formulations, market fragmentation, and future pipeline). The meeting tried to build on recent efforts to address the treatment gap in children and adolescents affected by HIV.

The meeting agenda, report and presentations are available for download here.


  Facebook Twitter LinkedIn

6 march 2014
The International AIDS Society (IAS) announces a new grant of £500,000 from ViiV Healthcare to support its Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)

4 December 2013
Launch of the CIPHER Online Paediatric HIV Cohort Database

11 December 2013
Janssen’s third-line drugs (DRV + ETV) donation programme for HIV-infected, treatment-experience children in sub-Saharan Africa

12 August 2013
The IAS-ILF Facebook and LinkedIn profiles are merged within the main IAS Facebook and LinkedIn profiles.

12 August 2013
FDA approves dolutegravir (Tivicay) for treatment of HIV infection

14 June 2013
Meeting event: Beyond Option B+
(30 June 2013 in Kuala Lumpur, Malaysia)

Meeting event: Expanding HIV Prevention Options for Women
(30 June 2013 in Kuala Lumpur, Malaysia)

19 February 2013
Meeting event: Sex and Gender Differences in ARV-Based Prevention Research
(3 March 2013 in Atlanta, Georgia, USA)

Articles from previous years are available here

Sponsoring Industry Partners

A list of previous sponsoring industry partners is available here